BMPR2 and hereditary hemorrhagic telangiectasia: A study by Lee et al. has shown that patients with PAH-HHT have significantly lower three-year survival rates compared to patients with a BMPR2 mutation or idiopathic PAH (53% vs. 74%) [87].